INMB Live signals | Maximize Profits with Getagraph.com

BUY 106720 min ago

@ $14.06

Issued: 14 Feb 2024 @ 15:50

Return: -19.70%

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease...

Stats
Today's Volume	77 647.00
Average Volume	102 282
Market Cap	211.12M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.540 ) 2024-05-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.76
ATR14	$0.0340 (0.30%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Moss David J	Buy	18 028	Common Stock
2024-04-19	Moss David J	Buy	18 028	Common Stock Warrants (right to buy)
2024-04-19	Tesi Raymond Joseph	Buy	18 028	Common Stock
2024-04-19	Tesi Raymond Joseph	Buy	18 028	Common Stock Warrants (right to buy)
2024-04-19	Lowdell Mark William	Buy	14 423	Common Stock

INSIDER POWER
97.72
Last 100 transactions
Buy: 3 367 309 \| Sell: 701 956

Volume Correlation

Long: 0.01 (neutral)

Short: -0.08 (neutral)

Signal:(33.659) Neutral

INmune Bio Inc Correlation

10 Most Positive Correlations
ECPG	0.878
FIVN	0.859
TREE	0.855
IPDN	0.844
PIRS	0.843
CWBR	0.833
LCFY	0.83
STX	0.828
NXST	0.828
PALT	0.826

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

INmune Bio Inc Correlation - Currency/Commodity

-0.39
( neutral )

-0.54
( weak negative )

0.00
( neutral )

-0.40
( neutral )

-0.28
( neutral )

0.74
( moderate )

INmune Bio Inc Financials

Annual	2023
Revenue:	$155 000
Gross Profit:	$155 000 (100.00 %)
EPS:	$-1.670

FY	2023
Revenue:	$155 000
Gross Profit:	$155 000 (100.00 %)
EPS:	$-1.670

FY	2022
Revenue:	$374 000
Gross Profit:	$374 000 (100.00 %)
EPS:	$-1.600

FY	2021
Revenue:	$-181 000
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.751

Financial Reports:

No articles found.

INmune Bio Inc

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Realtime updates for INmune Bio Inc [INMB]

Upcoming Earnings Alert